Cumberland Pharmaceuticals (CPIX) EBIAT (2016 - 2025)
Cumberland Pharmaceuticals (CPIX) has disclosed EBIAT for 16 consecutive years, with -$1.4 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 25.76% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 million through Dec 2025, up 55.83% year-over-year, with the annual reading at -$2.8 million for FY2025, 55.99% up from the prior year.
- EBIAT hit -$1.4 million in Q4 2025 for Cumberland Pharmaceuticals, up from -$1.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $1.3 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
- Historically, EBIAT has averaged -$1.2 million across 5 years, with a median of -$1.2 million in 2022.
- Biggest five-year swings in EBIAT: surged 233.79% in 2021 and later crashed 1089.92% in 2024.
- Year by year, EBIAT stood at -$3.8 million in 2021, then surged by 36.07% to -$2.5 million in 2022, then tumbled by 156.21% to -$6.3 million in 2023, then soared by 69.82% to -$1.9 million in 2024, then rose by 25.76% to -$1.4 million in 2025.
- Business Quant data shows EBIAT for CPIX at -$1.4 million in Q4 2025, -$1.9 million in Q3 2025, and -$735207.0 in Q2 2025.